Document Classification

Section Type: RESULTS

Text: In the efficacy trial, at six hours, nesiritide infusion at rates of 0. 015 and 0. 030 microg per kilogram per minute decreased pulmonary-capillary wedge pressure by 6. 0 and 9. 6 mm Hg, respectively (as compared with an increase of 2. 0 mm Hg with placebo, P < 0. 001), resulted in improvements in global clinical status in 60 percent and 67 percent of the patients (as compared with 14 percent of those receiving placebo, P < 0. 001), reduced dyspnea in 57 percent and 53 percent of the patients (as compared with 12 percent of those receiving placebo, P < 0. 001), and reduced fatigue in 32 percent and 38 percent of the patients (as compared with 5 percent of those receiving placebo, P < 0. 001).